CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
bevacizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00520013
NCT00520013Phase 2Completed
CompareCT.gov

A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Dana-Farber Cancer Institute·interventional·Posted Aug 23, 2007·Updated Jul 27, 2018

In Brief

A Phase 2 clinical trial evaluating bevacizumab, erlotinib, and 2 other interventions for Ovarian Cancer and 4 related conditions. Completed, enrolled 60 participants across 3 sites.

Detailed Summary

The purpose of this research study is to evaluate how patients with newly diagnosed advanced ovarian, fallopian tube, primary peritoneal cancer and papillary serous or clear cell mullerian tumors respond to consolidation therapy with Avastin and erlotinib or Avastin alone over 1 year. These drugs have been used in the treatment of other types of cancers and information from those studies suggests that these agents may help to treat the cancers studied here.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor, Clear Cell Mullerian Tumor
CountriesUnited States
CollaboratorsGenentech, Inc., Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2007
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2010
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.9 years ago

Interventions

bevacizumabdrug

erlotinibdrug

paclitaxeldrug

carboplatindrug